Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01755052 · ClinicalTrials.gov registry record
SILVER-AMI: Outcomes in Older Persons With Heart Attacks
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 3,042
- Enrollment target
NCT01755052: Completed study, sponsored by Yale University.
NCT01755052 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 3,042 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01755052 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 3,042 participants
- Enrollment target
Study Summary
SILVER-AMI is a research study of older persons who are admitted to the hospital with a heart attack. Patients will be interviewed in the hospital and again 6 months later. The researchers will also collect detailed medical record information to understand the effect of heart attacks on older persons. The research team at Yale University will use this information to develop a risk model that can be used to help doctors predict recovery. The goal of the study is to help older people in the future make well-informed decisions about their health care during a heart attack.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,042 participants |
| Start Date | 2013-01 |
| Est. Completion | 2018-06 |
What the finished NCT01755052 record still lists
NCT01755052 is an observational study that tracks outcomes without assigning an intervention. Its 3,042 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01755052 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01755052 about?
NCT01755052 is a clinical study titled "SILVER-AMI: Outcomes in Older Persons With Heart Attacks". SILVER-AMI is a research study of older persons who are admitted to the hospital with a heart attack. Patients will be interviewed in the hospital and again 6 months later. The researchers will also collect detailed medical record information to understand the effect of heart attacks on older person...
What is the current status of trial NCT01755052?
This trial is currently completed. The enrollment target is 3,042 participants. The study started on 2013-01. Estimated completion is 2018-06.
Who is sponsoring clinical trial NCT01755052?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07116967 · 3,040 participants · Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
- NCT06667700 · 3,082 participants · Phase 3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia